As of February 2023, Bremen recorded the highest second dose coronavirus (COVID-19) vaccination rate. The vaccination rollout in Germany began after the approval of the BioNTech-Pfizer vaccine in the EU. To be completely effective, the vaccine has to be administered in two doses, in two separate sessions. Booster vaccinations are also available. Other vaccines have also been approved in the EU since then.

Currently around 127.7 million coronavirus (COVID-19) vaccinations have taken place in Germany since the beginning of the campaign at the end of December 2020. The vaccination rollout followed the approval of the BioNTech-Pfizer vaccine in the EU. Other vaccines have since been allowed. Vaccinations are free and voluntary in Germany. The total number of vaccinations mentioned here includes both first and second doses. Most vaccines need to be administered in two doses to be effective against the virus.

In 2019, roughly 93 percent of German children starting school were vaccinated against tetanus in 2018. Other vaccinations for this group were against measles, mumps, and chicken pox.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Forecast: Total Influenza Vaccination Rates in Germany 2022 - 2026 Discover more data with ReportLinker!

The immunisation of measles in Germany saw no significant changes in 2021 in comparison to the previous year 2020 and remained at around 97.4 percent of children aged less than one year. Still, the immunisation reached its highest value in the observed period in 2021. Find more statistics on other topics about Germany with key insights such as number of annual dentist visits per capita and share of children immunized against hepatitis B.

The Germany Pneumococcal Vaccines Market Report is Segmented by Vaccine Type (Conjugate Vaccine, and Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, and Pneumovax23), and Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, and Government Authorities). The Report Offers the Value (in USD) for the Above Segments.

As of 2022, the BioNTech vaccine against the coronavirus (COVID-19) was administered the most in Germany. Figures were significantly higher for BioNTech vaccinations, compared to the other vaccines approved for use in the EU – Moderna, AstraZeneca and Janssen. BioNTech is a German biotechnological company, which developed a vaccine against COVID-19 in cooperation with U.S. pharmaceutical giant Pfizer.

New vaccines BioNTech and Moderna are mRNA vaccines, AstraZeneca is not, but all three have one thing in common – they have to be administered in two doses over a period of several weeks to provide protection against the virus. The Janssen vaccine, also referred to as Johnson & Johnson, referring to its manufacturer, requires one dose. Both BioNTech and Moderna vaccines have already been administered as booster shots while another coronavirus wave engulfs Germany. After initial shortages in deliveries at the beginning of Germany’s vaccination campaign at the end of December 2020, production has ramped up, also within the country, and the German government repeatedly assures the population that there are enough vaccines for first, second and booster shots.

The next wave Thus far there is no national vaccination mandate in Germany, though heated debate among political parties regarding the issue continues, particularly in the wake of rising coronavirus cases in the winter of 2021 and the emergence of the Omicron variant. While all the currently greenlighted vaccines against COVID-19 are not said to make the recipient immune to the virus, they are widely hailed as helping reduce the risk of a difficult illness or the possibility of a hospital stay.

Vaccination willingness against COVID-19 is generally perceived as low. Moreover, there is large heterogeneity across and within countries. As a whole, Germany has average vaccination rates compared to other industrialized countries. However, vaccination rates in the 16 different German federal states differ by more than 20 percentage points. We describe variation in vaccination rates on the level of the 400 German counties using data on all vaccinations carried out until December 2022. Around 52-72% of that variation can be explained by regional differences in demographic characteristics, housing, education and political party preferences. We find indications that the remaining part may be due to differences in soft factors such as risk aversion, trust in the German government, trust in science, and beliefs in conspiracy theories regarding the origins of the Corona virus. We conclude that improving the trust in science and the fight against conspiracy theories may possibly be effective tools to improve vaccination rates and effectively fight pandemics.

This dataset replicates all statistical models and figures from the study Left-Right-Position, Party Affiliation and Regional Differences Explain Low Covid-19 Vaccination Rates in Germany.

The Germany Pneumococcal Vaccines Market size was valued at USD 170.01 USD million in 2023 and is projected to reach USD 653.12 USD million by 2032, exhibiting a CAGR of 21.2 % during the forecast period. Vaccines that curb pneumococci infections caused by Streptococcus pneumoniae (pneumococcus) to vaccines which deter pneumococcal disease, Germany's Pneumococcal Vaccines Market has developed vaccines to guard against pneumococcal infections and pneumococcal disease. The vaccine could prevent babies from having pneumonia, meningitis, or other bloodstream infections. Vaccine types will include PCV, which will be used for children, adolescents, and even adults, to protect people against various strains of pneumococcal bacteria. On the other hand, pneumococcal polysaccharide vaccines (PPV) are typically administered in adults and older children, therefore they will be beneficial in providing vaccinated individuals with full Public education on the importance of vaccination, governments’ initiative to implement vaccination programs and the elderly who might get pneumococcal infection since they have lower immune system are the major factors which are positively affecting the Vaccinations against these diseases constitute a significant proportion of children (15 and below) due to the nature of the diseases and hence, they play an important role in protecting them against pneumococcal diseases and reducing the costs of the health system as well as improving public health. Key drivers for this market are: Increasing Public Awareness for Safer Medicines to Stimulate Market Value. Potential restraints include: Lack of Diagnosis and Treatment in Developing Countries to Limit the Demand for Wound Dressings . Notable trends are: Shift of Healthcare Providers from Medication to Electrical Stimulation for Treatment of Neurological Disorders to Fuel the Market.

The vaccination coverage against diphtheria, tetanus and whooping cough of German children remained mostly steady during the observed time period, amounting to 91 percent in 2021. These vaccinations are among the most common for children in Germany.

Characteristics by group.

Due to widespread Covid vaccination rates, the global trade in vaccines reached $42.5B, the highest level ever. Belgium topped the country rankings by the value of exports this year, followed by Germany and the U.S. Growing global demand stimulates the rapid expansion of Covid vaccine production facilities in the EU.

Pneumococcal vaccination rates with 95%-confidence intervals within two years in patients with “high-risk” condition for pneumococcal disease.

Snapshot img

Human Combination Vaccines Market Size 2024-2028

The human combination vaccines market size is forecast to increase by USD 7.03 billion at a CAGR of 8.69% between 2023 and 2028.

The market is experiencing significant growth due to several key trends and challenges. One of the primary drivers is the increasing antiviral drug resistance, which has led to a greater emphasis on preventive measures through vaccines. Additionally, the threat from bioterrorism has heightened the need for effective combination vaccines to protect against multiple diseases simultaneously. Vaccine distribution challenges, such as vaccine refrigeration and packaging, are significant considerations in the market. Furthermore, the consolidation of different immunization schedules is streamlining vaccine administration and increasing convenience for healthcare providers and patients. These trends are shaping the market and are expected to continue driving growth In the coming years.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses the production and distribution of vaccines that protect against multiple diseases with a single administration. This market is driven by the newborn population growth and the ongoing need for pediatric immunization. Inactivated virus vaccines and live attenuated vaccines are the primary types of combination vaccines, each offering unique advantages in terms of vaccine safety, effectiveness, and ease of administration. Immunization coverage rates vary globally, with ongoing efforts to increase vaccination adoption and combat vaccine resistance. The threat of bioterrorism and emerging infectious diseases further underscores the importance of vaccine development and immunization campaigns.
The global vaccine market is experiencing steady growth, fueled by advancements in vaccine technology, including pathogen inactivation and multi-dose vaccine administration. Vaccine compliance remains a crucial factor, with ongoing initiatives to improve vaccine safety, effectiveness, and vaccine compliance. The vaccine supply chain is a critical component of the market, with ongoing efforts to ensure a reliable and efficient distribution network. Disease prevention remains the primary focus of the market, with ongoing research and development aimed at addressing vaccine resistance and emerging diseases. The market is expected to continue growing, driven by the need to protect global populations from infectious diseases and ensure public health and safety.

How is this Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Inactivated vaccine
  Live attenuated vaccine


Channel

  Hospitals
  Retailers
  Online


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    Japan


  Rest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The inactivated segment dominates The market due to its superior tolerability and fewer complications when multiple antigens are used. Inactivated human combination vaccines, such as those for Chickenpox, DTaP, IPV, Pediarix, Pentacel, and Tetraxim, are preferred due to their ability to provide comprehensive protection against various diseases. However, producing these vaccines poses challenges due to potential antigen incompatibilities and interactions among ingredients. Inactivated vaccines are developed using pathogen particles that have been destroyed or killed, ensuring a strong immune response against the targeted organisms. Medical practitioners prioritize these vaccines due to their effectiveness in preventing diseases, including Diphtheria, Tetanus, Acellular pertussis, Polio, and Hib.

Get a glance at the market report of share of various segments Request Free Sample

The inactivated vaccine segment was valued at USD 8.8 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American market holds the largest share in 2023, driven by stringent regulatory policies mandating infant vaccination. Despite a slower growth rate due to decreasing infectious disease prevalence, the market expansion is fueled by ongoing initiatives to promote vaccine usage. In other regions, the market is driven by the rising incidence of di

Structural parameter estimates.

Vaccine administration in Germany fluctuated noticeably during the period displayed in this statistic. Peaking in 2007 at 47.6 million DDD (defined daily dose), figures dropped annually afterwards, increasing again from 2015 onwards. Germany offers various vaccinations for its citizens, and while not all of these are mandatory, many are strongly recommended. Inoculations usually start during babyhood at regular intervals explained by the German Standing Committee on Vaccination (STIKO), which is a part of the Robert Koch Institute. German vaccine market The WHO notes that vaccines are defined as pharmaceutical products in the legal sense, but they are also subject to additional regulation and control. These procedures are established both at the international and national level. Germany is among the leading five pharmaceutical markets in the world, following the U.S., China, and Japan. In 2019, vaccines generated over 713 million euros worth of revenue on the German pharmaceutical market. New ones get approved regularly, as is the case with the recent development of vaccines against the coronavirus (COVID-19). Currently, Germany is vaccinating its population with the following vaccines approved by the EMA (European Medicines Agency): BioNTech/Pfizer, Moderna, AstraZeneca, and Johnson & Johnson. Public opinion Opinions differ among the German population as to how effective vaccines are in preventing infectious diseases. Over half of respondents to a survey on the topic absolutely agreed, while a small percentage did not. Overall, in terms of vaccine knowledge in Europe, the majority of residents were sure that vaccines are subject to rigorous testing before being used. However, 55 percent also thought that vaccines weakened and overloaded the immune system instead of protecting it. Support for compulsory vaccinations was generally high in European countries.

Average marginal effects of individual characteristics on willingness to get vaccinated (N = 678, Pseudo R2 of underlying Logit estimation: 0.103).

As of May 2, 2023, the outbreak of the coronavirus disease (COVID-19) had spread to almost every country in the world, and more than 6.86 million people had died after contracting the respiratory virus. Over 1.16 million of these deaths occurred in the United States.

Waves of infections Almost every country and territory worldwide have been affected by the COVID-19 disease. At the end of 2021 the virus was once again circulating at very high rates, even in countries with relatively high vaccination rates such as the United States and Germany. As rates of new infections increased, some countries in Europe, like Germany and Austria, tightened restrictions once again, specifically targeting those who were not yet vaccinated. However, by spring 2022, rates of new infections had decreased in many countries and restrictions were once again lifted.

What are the symptoms of the virus? It can take up to 14 days for symptoms of the illness to start being noticed. The most commonly reported symptoms are a fever and a dry cough, leading to shortness of breath. The early symptoms are similar to other common viruses such as the common cold and flu. These illnesses spread more during cold months, but there is no conclusive evidence to suggest that temperature impacts the spread of the SARS-CoV-2 virus. Medical advice should be sought if you are experiencing any of these symptoms.